Literature DB >> 22639978

Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer's disease measured using the International Shopping List Test.

Yen Ying Lim1, Karra Harrington, David Ames, Kathryn A Ellis, Rebecca Lachovitzki, Peter J Snyder, Paul Maruff.   

Abstract

There is a need for culture neutral neuropsychological instruments. The International Shopping List Test (ISLT) is sensitive to memory impairment in Alzheimer's disease (AD) in different cultural groups, although its sensitivity to mild cognitive impairment (MCI) and ability to be given repeatedly at short retest intervals is unknown. Performance on the ISLT was compared between groups of healthy adults, MCI, and AD from the Australian Imaging Biomarkers and Lifestyle study of ageing. Subjects were assessed four times in three months. In each group, the ISLT performance measures had high test-retest reliability, and group means remained stable over time. There was no difference between groups on within-subject variability. These data suggest that in English-speaking samples, the ISLT is sensitive to MCI and can be given repeatedly in order to assess change in memory.

Entities:  

Mesh:

Year:  2012        PMID: 22639978     DOI: 10.1080/13803395.2012.689815

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  5 in total

1.  Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials.

Authors:  Andrew J Aschenbrenner; Jason Hassenstab; Guoqiao Wang; Yan Li; Chengjie Xiong; Eric McDade; David B Clifford; Stephen Salloway; Martin Farlow; Roy Yaari; Eden Y J Cheng; Karen C Holdridge; Catherine J Mummery; Colin L Masters; Ging-Yuek Hsiung; Ghulam Surti; Gregory S Day; Sandra Weintraub; Lawrence S Honig; James E Galvin; John M Ringman; William S Brooks; Nick C Fox; Peter J Snyder; Kazushi Suzuki; Hiroyuki Shimada; Susanne Gräber; Randall J Bateman
Journal:  Front Aging Neurosci       Date:  2022-06-16       Impact factor: 5.702

2.  The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.

Authors:  Xia Chen; Gabriël Jacobs; Marieke de Kam; Judith Jaeger; Jaakko Lappalainen; Paul Maruff; Mark A Smith; Alan J Cross; Adam Cohen; Joop van Gerven
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

3.  Change in retinal structural anatomy during the preclinical stage of Alzheimer's disease.

Authors:  Cláudia Y Santos; Lenworth N Johnson; Stuart E Sinoff; Elena K Festa; William C Heindel; Peter J Snyder
Journal:  Alzheimers Dement (Amst)       Date:  2018-02-07

4.  Visual and Verbal Serial List Learning in Patients with Statistically-Determined Mild Cognitive Impairment.

Authors:  Victor Wasserman; Sheina Emrani; Emily F Matusz; David Miller; Kelly Davis Garrett; Katherine A Gifford; Timothy J Hohman; Angela L Jefferson; Rhoda Au; Rod Swenson; David J Libon
Journal:  Innov Aging       Date:  2019-05-03

5.  A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease.

Authors:  Pradeep J Nathan; S Babli Millais; Alex Godwood; Odile Dewit; David M Cross; Janet Liptrot; Bharat Ruparelia; Stephen Paul Jones; Geor Bakker; Paul T Maruff; Gregory A Light; Alastair J H Brown; Malcolm Peter Weir; Miles Congreve; Tim Tasker
Journal:  Alzheimers Dement (N Y)       Date:  2022-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.